In late 2026, the industry is pivoting toward "Patient-Specific Toxicity Profiling." This year, a radical new class of "iPSC" (induced Pluripotent Stem Cell) platforms is being used to create lab-grown tissues from a specific patient's own cells. This innovation is a primary driver for the market, as it allows doctors to test how a high-stakes chemotherapy drug will affect a specific...